CryoPort, Inc. (CYRX)

Cryoport's stock price has been influenced by several key events in the past six months. The Q2 2025 earnings report showed strong revenue growth, but the stock experienced a decline in aftermarket trading despite analysts raising price targets. A strategic partnership with DHL Group and the divestiture of CRYOPDP were completed in June 2025, expected to enhance Cryoport's positioning in the APAC and EMEA regions. The launch of new integrated condition monitoring solutions by MVE Biological Solutions positively impacted the market. The Q3 2025 financial results reported a revenue increase and updated the full-year revenue guidance. The Q4 2024 financial results reported a revenue increase and guided for FY2025 revenue.

While Cryoport, Inc. operates in a growing market driven by the increasing demand for cell and gene therapies, specific detailed demand seasonality patterns for its products and services are not readily available in publicly accessible information. However, the company has historically noted growing interest and demand for cryogenic cold chain solutions in the life sciences, with a robust pipeline and favorable outlook driven by advancements in oncology and rare diseases.

Cryoport, Inc. is a global leader providing integrated temperature-controlled supply chain solutions for the life sciences industry, operating primarily within the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry, and also categorized under Manufacturing and Transport and Logistics. The company's core business revolves around ensuring the safe and reliable storage and delivery of critical therapies and biologic materials. Cryoport's major products and services are segmented into Life Sciences Services, which include temperature-controlled logistics, cryogenic biostorage, and bioservices, and Life Sciences Products, which offer cryogenic freezers, cryogenic dewars, and accessories.

Cryoport, Inc. maintains a strong global presence, with operations spanning the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), with the majority of its revenue generated from the Americas. In October 2025, Cryoport Systems strategically expanded its global supply chain center network by launching a new state-of-the-art facility in Louvres, France, near the Paris Charles de Gaulle Airport. The company is headquartered in Brentwood, Tennessee, United States.

Cryoport, Inc. has focused on strengthening its brand reputation through strategic initiatives, including a comprehensive rebranding effort in January 2024 to unify its four business units under one cohesive identity. This collaborative approach has garnered industry attention, leading to increased brand awareness and recognition in life science publications. In October 2024, Cryoport, Inc. was recognized as a finalist in the Life Science Sales & Marketing Awards.

Cryoport, Inc. has significant institutional ownership, with 319 institutional owners and shareholders holding a total of 53,511,645 shares. Major institutional owners include Cadian Capital Management, Lp, Morgan Stanley, BlackRock, Inc., Vanguard Group Inc, Brown Capital Management Llc, Millennium Management Llc, Fred Alger Management, Llc, Thematics Asset Management, Assenagon Asset Management S.A., and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Institutional ownership accounts for approximately 81.7% of the company's shares, while individual insiders hold about 3.26%.